Genocea Biosciences (GNCAQ) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsShort InterestTrendsBuy This Stock GNCAQ vs. VRPX, SCPS, VAXX, EVLO, CMRA, GNCA, ARDS, CALA, STAB, and AMPEShould you be buying Genocea Biosciences stock or one of its competitors? The main competitors of Genocea Biosciences include Virpax Pharmaceuticals (VRPX), Scopus BioPharma (SCPS), Vaxxinity (VAXX), Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), Genocea Biosciences (GNCA), Aridis Pharmaceuticals (ARDS), Calithera Biosciences (CALA), Statera Biopharma (STAB), and Ampio Pharmaceuticals (AMPE). These companies are all part of the "pharmaceutical products" industry. Genocea Biosciences vs. Its Competitors Virpax Pharmaceuticals Scopus BioPharma Vaxxinity Evelo Biosciences Comera Life Sciences Genocea Biosciences Aridis Pharmaceuticals Calithera Biosciences Statera Biopharma Ampio Pharmaceuticals Virpax Pharmaceuticals (NASDAQ:VRPX) and Genocea Biosciences (NASDAQ:GNCAQ) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and institutional ownership. Which has stronger earnings & valuation, VRPX or GNCAQ? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVirpax PharmaceuticalsN/AN/A-$15.19MN/AN/AGenocea BiosciencesN/AN/AN/AN/AN/A Which has more volatility and risk, VRPX or GNCAQ? Virpax Pharmaceuticals has a beta of 1.49, meaning that its share price is 49% more volatile than the S&P 500. Comparatively, Genocea Biosciences has a beta of 1.74, meaning that its share price is 74% more volatile than the S&P 500. Is VRPX or GNCAQ more profitable? Genocea Biosciences' return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Virpax PharmaceuticalsN/A -1,554.34% -338.29% Genocea Biosciences N/A N/A N/A Do analysts recommend VRPX or GNCAQ? Given Genocea Biosciences' higher probable upside, analysts plainly believe Genocea Biosciences is more favorable than Virpax Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virpax Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Genocea Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media favor VRPX or GNCAQ? In the previous week, Virpax Pharmaceuticals' average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score. Company Overall Sentiment Virpax Pharmaceuticals Neutral Genocea Biosciences Neutral Do insiders & institutionals hold more shares of VRPX or GNCAQ? 32.2% of Virpax Pharmaceuticals shares are owned by institutional investors. 3.7% of Virpax Pharmaceuticals shares are owned by insiders. Comparatively, 1.6% of Genocea Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. SummaryGenocea Biosciences beats Virpax Pharmaceuticals on 4 of the 7 factors compared between the two stocks. Get Genocea Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for GNCAQ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GNCAQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GNCAQ vs. The Competition Export to ExcelMetricGenocea BiosciencesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$6K$282.56M$5.72B$9.77BDividend YieldN/AN/A3.77%4.10%P/E RatioN/AN/A30.9025.26Price / SalesN/A578.14403.8188.28Price / CashN/A22.4425.2228.45Price / BookN/A9.939.516.00Net IncomeN/A-$115.81M$3.26B$265.34M Genocea Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNCAQGenocea BiosciencesN/AN/AN/AN/A$6KN/A0.0070VRPXVirpax PharmaceuticalsN/A$0.01flatN/A-99.9%$14KN/A0.007SCPSScopus BioPharmaN/A$0.00flatN/AN/A$13KN/A0.009VAXXVaxxinityN/A$0.00-99.8%N/A-57.0%$13KN/A0.0090Gap DownHigh Trading VolumeEVLOEvelo BiosciencesN/A$0.00flatN/AN/A$9KN/A0.00120CMRAComera Life SciencesN/A$0.00flatN/AN/A$6K$1.00M0.002GNCAGenocea BiosciencesN/AN/AN/AN/A$6K$1.91M0.0070ARDSAridis PharmaceuticalsN/A$0.00flatN/AN/A$5KN/A0.0030CALACalithera Biosciences0.5989 of 5 stars$0.00flatN/A-92.0%$5KN/A0.0060STABStatera BiopharmaN/A$0.00flatN/AN/A$5KN/A0.0020AMPEAmpio PharmaceuticalsN/A$0.00flatN/A+22.7%$3KN/A0.0020 Related Companies and Tools Related Companies Virpax Pharmaceuticals Competitors Scopus BioPharma Competitors Vaxxinity Competitors Evelo Biosciences Competitors Comera Life Sciences Competitors Genocea Biosciences Competitors Aridis Pharmaceuticals Competitors Calithera Biosciences Competitors Statera Biopharma Competitors Ampio Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GNCAQ) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersBiotech Alert: With news on MPox, RSV, and more, this tiny firm could disrupt a $3B marketA small biotech is stepping into the spotlight with a first-in-class antiviral platform—and it could be one of...Smallcaps Daily | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | Sponsored"AI Upgrade" Coming Sept. 1stA new “AI Upgrade” is rolling out on September 1st—and tech leaders are calling it transformational. Softbank’...Behind the Markets | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genocea Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genocea Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access